CD33 and neoplasm: Gemtuzumab ozogamicin (GO) is a CD33-targeted antibody–drug conjugate (ADC) linked to calicheamicin, that specifically targets the membrane antigen CD33 and releases a derivative of the cytotoxic calicheamicin component after internalization, leading to tumor cell death [155, 156].